In vivo tumor targeting of ODN-PEG-folic acid/PEI polyelectrolyte complex micelles
Source abstract
Abstract
A tumor-targeting antisense oligodeoxynucleotide (ODN) delivery system based on polyelectrolyte complex (PEC) micelles is demonstrated. ODN-PEG-folic acid (ODN-PEG-FA) was synthesized using a heterofunctional PEG linker. The PEC micelles for the targeted ODN delivery to tumor cells were produced by ionic interactions between the ODN-PEG-FA and polyethylenimine (PEI). The in vivo targeting properties of the PEC micelles were assessed using a mouse tumor model. The size of ODN-PEG-FA/PEI PEC micelles was 92.3 nm with a relatively narrow distribution. Cellular uptake of the ODN-PEG-FA/PEI PEC micelles by folic acid receptor over-expressing cells (KB) was greatly enhanced compared to that of ODN-PEG/PEI PEC micelles. When the ODN-PEG-FA/PEI PEC micelles were systemically administered to the mice bearing KB cell xenograft tumor, ODN was accumulated to the solid tumor in a target specific manner. This study suggests that the PEC micelles with a receptor-recognizable targeting ligand on the surface have potential for passive and active targeted delivery of ODN drugs to cancer cells.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (27)
Show source-provided references
1. 10.1126/science.107020010.1126/science.1070200 ↗
2. Wagner E. · Biomed. Pharmacother. · 2004 · 58 · 15210.1016/j.biopha.2004.01.003 ↗
3. 10.1021/bc025608710.1021/bc0256087 ↗
4. Ginobbi P. · Anticancer Res. · 1997 · 17 · 29
5. 10.1038/sj.gt.330135110.1038/sj.gt.3301351 ↗
6. Benns J. M. · J. Drug Target. · 2001 · 9 · 12310.3109/10611860108997923 ↗
7. 10.1016/S0167-4781(98)00274-710.1016/S0167-4781(98)00274-7 ↗
8. Yabe Y. · J. Pharmacol. Exp. Ther. · 1999 · 289 · 117610.1016/S0022-3565(24)38250-3 ↗
9. 10.1016/S0168-3659(00)00340-010.1016/S0168-3659(00)00340-0 ↗
10. Yoo H. S. · J. Control. Rel. · 2002 · 82 · 1710.1016/S0168-3659(02)00088-3 ↗
11. 10.1021/bc010052t10.1021/bc010052t ↗
12. 10.1021/ma961217+10.1021/ma961217+ ↗
13. Bader H. · Angew. Makromol. Chem. · 1984 · 124 · 45710.1002/apmc.1984.051230121 ↗
14. 10.1016/0014-5793(90)81016-H10.1016/0014-5793(90)81016-H ↗
15. Kwon G. · Adv. Drug Deliv. Rev. · 1996 · 16 · 10710.1016/S0169-409X(96)00401-2 ↗
16. 10.1021/bc025632k10.1021/bc025632k ↗
17. 10.1016/j.jconrel.2003.07.00210.1016/j.jconrel.2003.07.002 ↗
18. 10.1016/S0169-409X(02)00042-X10.1016/S0169-409X(02)00042-X ↗
19. Wang S. · Proc. Natl. Acad. Sci. USA · 1995 · 93 · 331810.1073/pnas.92.8.3318 ↗
20. 10.1023/A:101194691520910.1023/A:1011946915209 ↗
21. 10.1021/bm034164u10.1021/bm034164u ↗
22. 10.1021/bc950070910.1021/bc9500709 ↗
23. Vinogradof S. · Bioconjug. Chem. · 1999 · 10 · 85110.1021/bc990037c ↗
24. 10.1016/j.jconrel.2004.02.00310.1016/j.jconrel.2004.02.003 ↗
25. Harada-Shiba M. · Gene Ther. · 2002 · 9 · 40710.1038/sj.gt.3301665 ↗
26. Matsumura Y. · Cancer Res. · 1986 · 46 · 6387
27. 10.1016/S0168-3659(01)00309-110.1016/S0168-3659(01)00309-1 ↗